Cardiac rehabilitation to improve health-related quality of life following trans-catheter aortic valve implantation: a randomised controlled feasibility study: RECOVER-TAVI Pilot, ORCA 4, for the Optimal Restoration of Cardiac Activity Group by Rogers, Paula et al.
Rogers et al. Pilot and Feasibility Studies           (2018) 4:185 
https://doi.org/10.1186/s40814-018-0363-8RESEARCH Open AccessCardiac rehabilitation to improve
health-related quality of life following
trans-catheter aortic valve implantation:
a randomised controlled feasibility study
RECOVER–TAVI Pilot, ORCA 4, For the Optimal Restoration of
Cardiac Activity Group
Paula Rogers1,2, Sayed Al-Aidrous1,2, Winston Banya1,2, Shelley Rahman Haley1,2, Tarun Mittal1,2, Tito Kabir1,2,
Vasileois Panoulas1,2, Shahzad Raja1,2, Sunil Bhudia1,2, Heather Probert1,2, Claire Prendergast1,2, Mark S. Spence2,
Simon Davies1,2, Neil Moat1,2, Rod S. Taylor3 and Miles Dalby1,2*Abstract
Objectives: Transcatheter aortic valve implantation (TAVI) is often undertaken in the oldest frailest cohort of patients
undergoing cardiac interventions. We plan to investigate the potential benefit of cardiac rehabilitation (CR) in this
vulnerable population.
Design: We undertook a pilot randomised trial of CR following TAVI to inform the feasibility and design of a future
randomised clinical trial (RCT).
Participants: We screened patients undergoing TAVI at a single institution between June 2016 and February 2017.
Interventions: Participants were randomised post-TAVI to standard of care (control group) or standard of care plus
exercise-based CR (intervention group).
Outcomes: We assessed recruitment and attrition rates, uptake of CR, and explored changes in 6-min walk test,
Nottingham Activities of Daily Living, Fried and Edmonton Frailty scores and Hospital Anxiety and Depression
Score, from baseline (30 days post TAVI) to 3 and 6 months post randomisation. We also undertook a parallel
study to assess the use of the Kansas City Cardiomyopathy Questionnaire (KCCQ) in the post-TAVI population.
Results: Of 82 patients screened, 52 met the inclusion criteria and 27 were recruited (3 patients/month). In the
intervention group, 10/13 (77%) completed the prescribed course of 6 sessions of CR (mean number of sessions
attended 7.5, SD 4.25) over 6 weeks. At 6 months, all participants were retained for follow-up. There was apparent
improvement in outcome scores at 3 and 6 months in control and CR groups. There were no recorded adverse
events associated with the intervention of CR. The KCCQ was well accepted in 38 post-TAVI patients: mean summary
score 72.6 (SD 22.6).
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Conclusions: We have demonstrated the feasibility of recruiting post-TAVI patients into a randomised trial of CR. We
will use the findings of this pilot trial to design a fully powered multicentre RCT to inform the provision of CR and
support guideline development to optimise health-related quality of life outcomes in this vulnerable population.
Retrospectively registered 3rd October 2016 clinicaltrials.gov NCT02921880.
Trial registration: Clinicaltrials.Gov identifier NCT02921880
Keywords: Cardiac rehabilitation, Transcatheter aortic valve implantation, Randomised controlled trial, Pilot studyIntroduction
The prevalence of aortic stenosis (AS) is rising in an age-
ing population and carries significant risk [1, 2]. If left
untreated, symptomatic severe aortic stenosis can have a
mortality of 75% at 3.5 years with up to 50% of dying
suddenly [3].
Transcatheter aortic valve implantation (TAVI) has
been shown to be superior to medical management and
at least equivalent to surgical replacement in high and
intermediate risk patients for short and intermediate
term clinical outcomes [4]. As a consequence, TAVI has
caused a paradigm shift by providing a percutaneous
alternative to surgical aortic valve replacement and over
the past 15 years over 100,000 TAVI procedures have
been undertaken with recent-meta analysis reporting a
mean patient age of 81.5 years [5].
The World Health Organization defines health as not
merely the absence of disease but rather a more complex
interplay between social and medical factors resulting in
a holistic sense of wellbeing [6]. This interaction is of
greater consequence in the elderly whose frailty, multiple
co-morbidities, advanced age and reduced reserve result
increased procedural morbidity and mortality [7, 8].
Whilst pivotal randomised trials focus on five key out-
come measures of mortality, stroke, paravalvar leak,
pacemaker requirement and vascular access complica-
tions, these are not the sole metrics of clinical success:
Hospital readmission is common occurring in up to half
of patients at 1 year with a high prevalence of heart fail-
ure and significant morbidity [9]. Furthermore, heart
failure patients regard good levels of functional outcome
and health-related quality of life (HRQoL) equally or
more important than improvements in mortality [10].
Large randomised studies have addressed disease specific
and generic measures of HRQoL but these have been
limited to the impact of the TAVI intervention itself ra-
ther than optimising the subsequent outcome [11].
Frailty is a particularly important syndrome of multiple
impairments in patients with cardiovascular disease [12]
and whilst difficult to quantify is associated with in-
creased vulnerability to stressors [13].
Cardiac rehabilitation (CR) is a multi-faceted intervention
that not only improves quality of life and reducesdepression, but has also been shown to reduce hospital ad-
missions and disease-specific mortality in post-myocardial
infarction, revascularisation and heart failure populations
[14–16]. As a consequence, CR is mandated in national
and international guidelines for these indications [17–20].
Although some small studies have been reported [21, 22],
CR has not yet been investigated in in post TAVI patients
in a randomised controlled trial (RCT) powered on HRQoL
or clinical events. CR’s focus on education, lifestyle inter-
vention and exercise renders it particularly important in
frailer higher risk individuals who undergo TAVI. In
addition, the elderly are often under-represented in clinical
trials with trial design, logistical and financial factors being
cited as obstacles to recruitment [23].
We therefore undertook a pilot RCT to inform the
feasibility and design of a future fully outcome powered
multicentre randomised trial of CR after TAVI. Specific
study objectives were to (1) assess recruitment rates; (2)
assess acceptability and uptake of CR and quantify the
delivery of CR in this population; (3) assess attrition
rates; (4) explore the impact of CR on functional, inde-
pendence, frailty and emotional outcomes 30 days post
TAVI (baseline) and post-CR at 3 and 6 months; and (5)
assess suitability of the use of the Kansas City Cardiomy-
opathy Questionnaire (KCCQ) in a separate post TAVI
cohort.
Methods
This study is reported in accordance with the CON-
SORT extension for pilot and feasibility trials [24]
(Additional file 1).
Trial design
RECOVER-TAVI is a single-centre pilot RCT in patients
who have undergone TAVI. Patients were randomly allo-
cated 4 weeks after their TAVI procedure in a 1:1 ratio
with allocation administered by an investigator inde-
pendent of the study, stratified by age and gender to
either standard of care (SOC; control group) or CR plus
SOC (intervention group). Outcomes were measured
30 days post TAVI (baseline), and at 3 and 6 months
post randomisation by an assessor blinded to group
allocation.
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All patients scheduled for TAVI at our centre between
June 2016 and March 2017 were screened for trial inclu-
sion. Patients were included if they fulfilled the following:
Severe symptomatic aortic stenosis accepted for TAVI in
our institutional Multidisciplinary Team Meeting, age ≥
75 years, able to give written informed consent, and in the
Investigator’s opinion, able to comply with all study re-
quirements. Study exclusions were CR deemed inappro-
priate due to co-morbidity or frailty, life expectancy less
than 1 year due to co-morbidity, previous AVR or TAVI,
or predominant aortic regurgitation.Ethics approval and consent to participate
Written informed consent was given prior to the TAVI
procedure (rather than during post procedure recovery)
(Additional file 2).Control and intervention groups
Patients randomised to the control group received SOC
according to our institutional protocols. Patients rando-
mised to the intervention group underwent a compre-
hensive biopsychosocial assessment with a member of
the exercise team, initiated 1-month post procedure and
comprised of once weekly sessions for 60–90 min for six
sessions. An individualised programme was prescribed
for each patient based on information gained from their
functional capacity test and discussion around their spe-
cific goals. Exercise was prescribed following the Fre-
quency, Intensity, Time and Type (FITT) principle and a
moderate intensity interval approach was used based on
the Association of Chartered Physiotherapists in Cardiac
Rehabilitation (ACPICR) Standards [25]. To monitor ex-
ercise response, ambulatory 3 lead ECG recordings were
recorded (C.Net 5000, Cardionetics, UK), heart rate
(HR) monitors (Polar Watch, Polar T31 FS2, Polar Elec-
tro, Finland) and the Borg rating of perceived exertion
scale were used (ACPICR). Exercise prescription con-
sisted of graduated cardiovascular training and resistance
training (both upper and lower body) using cardiovascu-
lar exercise machines (treadmill and bike) as well as
functional exercise such as ‘sit to stand’. After each exer-
cise session, each individual’s prescription was reviewed
and altered appropriately for the subsequent session.
The intensity of the exercise was progressively increased
based on the self-reported BORG intensity.
Patients were offered further sessions if able to attend,
in line with our institutional programme and the British
Association for Cardiovascular Prevention and Rehabili-
tation (BACPR) recommendations [26, 27]. Prior to
1-month post-TAVI, patients did not undergo formal re-
habilitation though were given general advice regarding
early mobilisation as per usual care.Both control and intervention groups received routine
medical care which included an outpatient clinic
follow-up appointment, appropriate drug therapy and
concomitant medical management of co-morbidities
according to local practice.
Outcomes
Baseline characteristics were collected at randomisa-
tion (30 days post TAVI) and study outcomes mea-
sured at baseline (pre-randomisation), and 3 months
and 6 months post-randomisation. Feasibility out-
comes of this study were: recruitment rate (i.e. aver-
age number of patients/month willing to give
informed consent and be randomised into a trial of
CR post TAVI); acceptability and uptake of CR and
quantification the delivery of CR; and attrition rates
(i.e. proportion of patients who provided outcomes at
3- and 6-months follow-up). We collected the follow-
ing patient-related outcomes: 6-minute walk test
(6MWT) [28], Nottingham Activities of Daily Living
(ADL, scale of 0 for least activity to 22 for most ac-
tivity) [29], FRIED Frailty score (0 = not frail, 1–2 =
pre-frail, 3 = frail) [30], Edmonton Frailty Score (9 do-
mains, scale of 0 for non-frail to 17 for severely frail)
[31] and Hospital Anxiety and Depression Scores
(HADS, 0–7 normal, 8–10 borderline, 11–21 abnor-
mal) Score [32].
Following the start of the pilot study, due to the diffi-
culty in measuring the study outcome measures and
considering the primary objective of informing the de-
sign of a subsequent clinical outcome powered study we
decided to incorporate a disease-specific HRQoL parallel
observational sub-study to assess the acceptability and
applicability of the KCCQ in a cohort of post-TAVI pa-
tients [33].
Blinding
Given the nature of the intervention in this study, neither
participants nor clinicians were blinded to group alloca-
tion. Outcome assessors were however blinded to group.
Statistical methods
Given the pilot design of this study we based the sample
size on the feasibility objective of informing the planning of
a definitive trial, rather than on formal power calculation to
detect between-group difference for patient outcomes.
Considering a likely ‘moderate’ effect size of the CR inter-
vention we estimated that approximately 15 patients per
group would be required to inform the design of a defini-
tive trial [34]. Patient reported outcomes for both groups
were reported descriptively according to intention-to-treat
principle (i.e. according to initial random allocation) at all
time points using the mean (standard deviation, SD) or me-
dian (range). Categorical data were presented as number
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by the difference in means between the 2 groups and pre-
sented as means and 95% CIs. All data analyses were
undertaken using version 14.1 of Stata software [35].
Patient and public involvement
Patients and their carers were involved in the study
design before the application for funding was submitted.
The lay summary was prepared and discussed with
patients in the out-patient department and ward areas.
Patients with and without aortic stenosis were
approached to comment on the study design. Overall,
the patients who were surveyed said that they would be
happy to be approached to take part in the study. Some
patients were happy that the choice to undertake cardiac
rehabilitation would be re-affirmed at 4 weeks post im-
plant, rather than in the immediate post-operative
period. Some patients felt that the study offered a robust
plan of follow-up in which patients would feel reassured.
Travel expenses were commented on as being an issue
for some people and it was explained that a budget
would be secured to reimburse travel costs.
The patient feedback was incorporated into the Re-
search Ethics Committee application and the overall
study design. Patients were invited to receive a lay sum-
mary of the study findings at the end of the project.
Results
A total of 82 patients scheduled for TAVI were
screened of whom 52 were eligible for study recruit-
ment. Of these, 20 declined; most frequently due to
concerns about travel or they chose not to give a spe-
cific reason. Study recruitment was extended from 30
to 32 because two patients ultimately did not undergo
TAVI for technical reasons. Three patients withdrew
after TAVI; two for no given reason and one died.
Therefore, 27 patients were randomised (33% of those
screened). Following randomisation one participant in
each group switched to the other arm through patient
choice. Thirteen of the control group patients com-
pleted the study assessment. Ten of the 13 Intervention
group completed the CR and assessment, three being
too unwell to do so, and all patients were followed up.
Ultimately therefore, 23 patients (28% of those
screened) were enrolled in the study and completed the
study interventions, with the exception that only 14 of
the study patients underwent the 6MWT due to frailty
(Fig. 1 and Table 1).
Baseline characteristics
The overall study mean age was 82 years and the major-
ity of participants (55%) were male. There was some evi-
dence of imbalance in baseline outcome scores between
groups, with 6-min walk distance being greater and leftventricular ejection fraction being numerically greater in
the control group than the intervention group (Table 1,
Additional file 3) most likely due to the play of chance
in small groups.
Recruitment and attrition
 Thirty-two patients were recruited over 10 months
indicating a recruitment rate of 3.2 patients per
month (Fig. 2)
 There was 100% retention of participants in the
study and no loss to follow up (Fig. 1).
CR delivery and follow-up
Ten (77%) participants in the intervention group completed
the prescribed course of 6 sessions. The average number of
sessions completed was 7.5 (SD 4.25). Three participants
completed more than the six prescribed sessions attending
15, 13 and 12 sessions respectively. We were able to retain
all control and intervention participants over the 6-months
of the study and no patients were lost to follow. One control
participant died prior to the 6 month follow-up due to a
non-cardiac cause. The logistical considerations and costs of
the CR intervention were defined. There were no recorded
adverse events associated with the intervention of CR.
Functional, Independence, frailty and emotional
outcomes
There were improvements at 3 and 6 months in 6-min
walk test, Nottingham activities of daily living, FRIED
Frailty Score, Edmonton frailty score and Hospital Anx-
iety and Depression score in both groups. There was no
apparent difference between the control and interven-
tion groups however at 3 or 6 months (Tables 2 and 3
Additional file 4).
Adverse events
There were no recorded adverse events associated with
the intervention group.
TAVI KCCQ sub-study
Thirty-eight separate post-TAVI patients completed the
KCCQ with a mean clinical summary score of 73.6 (SD
21.6) and mean overall summary score of 72.6 (SD 22.6)
(Table 4, Additional file 5). The characteristics of partici-
pants in this sub-study were similar to those in the pilot
study.
Discussion
We achieved the primary objective of this pilot study
and demonstrated the feasibility and acceptability of re-
cruitment and retention in an elderly post TAVI cohort
of participants in the context of a randomised clinical
trial of CR.
Fig. 1 RECOVER-TAVI CONSORT flow diagram
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around delivering CR for this post TAVI population in
the context of a future randomised trial.
There were baseline imbalances in 6-min walk test,
and left ventricular function between the groups which
may have affected the outcome and the study was not
powered to measure the efficacy of CR.
There were a number of key learning points which will
inform the design of an outcome powered study:
The investigators, although experienced in clinical
frailty assessment reported that questionnaires were not
always easy to administer and quantifiable differences
between the scores were not easy to measure, especially
for frailty scores.
In the parallel KCCQ clinical quality HRQoL audit the
average age and comorbidity profile was similar to the
trial cohort and the Overall Summary and Clinical Sum-
mary KCCQ score and standard deviation were defined.
In particular, the KCCQ level was similar to thatreported in large clinical trials following TAVI and is
likely to generalizable to a wider multicentre population
for a subsequent trial.
Of note, the CR intervention was started at day 30
post-TAVI because of concerns about vascular access
discomfort/complications. In the event, it was felt by the
CR team that most patients could have started the CR
earlier when potentially its impact would have been
greater.
Anecdotally, the CR team were often asked about
medical management such as clarifying drug regimens
and where necessary, opportunistic scheduling of clinic
appointments was facilitated potentially reducing re-
admission rates.
Our study has a number of limitations. There was a
disparity in the baseline characteristics between the con-
trol and intervention groups. As it was a single-centre
trial, our findings have limited generalisability—though
we adopt similar treatment pathways and clinical
Table 1 Baseline characteristics for randomised pilot study
All Participants (n = 27) Control group (n = 14) Intervention group (n = 13)
Male, n (%) 12 (44.4) 6 (42.9) 6 (46.2)
Age: mean (SD) 82.04 (4.8) 81.21 (3.6) 82.92 (6.0)
BMI: mean (SD) 27.70 (4.2) 28.13 (4.9) 27.24 (3.6)
Diabetes, n (%) 4 (14.8) 3 (21.4) 1 (7.7)
Smoking: never n (%) 13 (48.1) 7 (50.0) 6 (46.2)
Ex, n (%) 14 (51.9) 7 (50.0) 7 (53.8)
Creatinine: mean (SD) 95.3 (28.1) 90.0 (23.9) 101.0 (32.0)
Previous MI, n (%) 5 (18.5) 2 (14.3) 3 (23.1)
History of pulmonary disease, n (%) 7 (25.9) 4 (28.6) 3 (23.1)
Pre-operative arrhythmia, n (%) 15 (55.6) 7 (50.0) 8 (61.5)
Previous cardiac surgery, n (%) 7 (25.9) 3 (21.4) 4 (30.8)
Previous PCI, n (%) 11 (40.7) 5 (35.7) 6 (46.2)
Left ventricular ejection fraction, n (%)
≥ 50% 21 (77.8) 12 (85.7) 9 (69.2)
30–49% 5 (18.5) 2 (14.3) 3 (23.1)
< 30% 1 (3.7) 0 1 (7.7)
6-min walk (metres)* 346.9(44.7) 401.0(41) 325.2(22.8)
FRIED scale 0 n (%) 3/25 (12.0) 2/12 (16.7) 1 (7.7)
1, n (%) 9/25 (36.0) 3/12 (25.0) 6 (46.2)
2, n (%) 8/25 (32.0) 5/12 (41.7) 3 (23.1)
3, n (%) 5/25 (20.0) 2/12 (16.7) 3 (23.1)
Nottingham EADL (0–22) * 15.7 (3.9) 14.8 (4.7) 16.5 (3.0)
Edmonton Frail Scale (0–17) * 5.17 (1.9) 5.25 (1.8) 5.08 (2.2)
HADS Anxiety (0–21) ** 3.0 (2, 4) 3.0 (2, 5) 3.0 (2, 4)
HADS Depression (0–21) ** 2.0 (1, 5) 2.0 (1, 4) 2.0 (2, 5)
*Mean (SD)
**Median (inter-quartile range)
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groups who have indicated willingness to engage in a
multicentre trial. Given the small sample size, the study
was not powered to formally compare the changes in
outcomes within or between groups. We could have
studied more outcomes including the KCCQ and othersFig. 2 RECOVER TAVI recruitment timelinein the randomised trial but administering the assessment
tools is time consuming and patient fatigue becomes a
significant problem reducing both quality of assessment
and patient acceptance, thus we studied the KCCQ in a
separate audit of similar patients.
In this pilot we elected first to assess the acceptability to
this frail cohort of a relatively modest intensity and dur-
ation of CR. Although this was a pilot study not powered
for HRQoL or frailty outcomes, the lack of any signal of
difference between the CR and SOC groups might suggest
that intensifying the CR intervention may be appropriate.
In addition, the fact that the majority of patients com-
pleted the CR course and that some elected for further CR
indicates that a more intensive and longer course may be
acceptable to this cohort for a subsequent trial.
Implications for planning a future trial
This pilot study has demonstrated the feasibility of per-
forming a multicentre trial of SOC vs CR in a post TAVI
population.





Treatment effect (95% CI)
6-min walk (metres) * 370.0 (33) 319.7 (24.5) − 50.33 (− 171.1, 70.4)
FRIED Scale 0 1/14 (7.1%) 2/11 (18.2%)
1 6/14 (42.9%) 5/11 (45.4%)
2 6/14 (42.9%) 1/11 (9.1%)
3 1/14 (7.1%) 3/11 (27.3%)
Nottingham EADL (0–22)* 17.8 (1.8) 18.2 (2.5) 0.4 (−1.4, 2.1)
Edmonton Frail Scale (0–17)* 4.50 (2.0) 4.4 (1.7) − 0.1 (−1.7, 1.4)
HADS Anxiety (0–21)** 2 (1, 5) 3 (2, 4.5) 0 (−3, 2)
HADS Depression (0–21)** 3.5 (1, 5) 3.5 (2, 6.5) 1 (−2, 3)
*Mean (SD)
**Median (inter-quartile range)
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study indicating that over a two-year period we could
anticipate recruiting 72 patients. The pilot and proposed
outcome powered trial have been presented at a Na-
tional Meeting and ten centres approached have indi-
cated willingness to participate.
Specifically, CR was acceptable to this patient cohort
with excellent participant retention. We are planning a
multicentre outcome powered HRQoL study of SOC vs
CR for patients who have received TAVI to inform clin-
ical practice, optimise patient outcomes and support
guideline development.
Pragmatically we have successfully adopted the simple
approach of using established CR programs rather that
developing a TAVI-specific programme which would be
expensive and logistically challenging. We plan to con-
tinue this approach for a subsequent clinical outcome
powered trial.
Participating centres will be required to have a
centre-based CR programme preferably with BACPR
accreditation. We plan to deliver CR earlier post-TAVITable 3 Outcomes at 6 months
Control group
N = 14
6-min walk (metres)* 385.5 (84.3)




Nottingham EADL (0–22) * 17.33 (2.9)
Edmonton Frail Scale (0–17) * 4.58 (1.9)
HADS Anxiety (0–21) ** 3.0 (2, 5)
HADS Depression (0–21) ** 2 (1,45)
*Mean (SD)
**Median (Inter-quartile range)and to increase the intensity and duration for the
CR to three sessions per week for 12 weeks and
starting earlier than day 30. Although we selected
patients > 75 years of age, TAVI is now being under-
taken in significant numbers of younger patients,
often with complex comorbidities who may benefit
from CR and we may need to consider reducing or
omitting the age cut-off.
The 6-month follow-up period was dictated by finan-
cial and resource implications in this pilot however in a
subsequent funded clinically powered study we propose
a 1-year follow-up period.
Considering our experience of the complex issues
around frailty independence and emotional assessment
in this cohort, we are exploring other HRQoL measures
including KCCQ as the primary outcome measure. Sec-
ondary outcome measures will include exercise capacity
(e.g. 6-min walk test), mortality, hospital readmission
rates, mortality, psychological well-being (e.g. HADS),
generic HRQoL (SF-12 and EQ-5D-5L), physical activity
(accelerometer) and health care utilisation.Intervention group
N = 13
Treatment effect (95% CI)





18.0 (2.3) 0.7 (−1.5, 2.8)
5.15 (2.4) 0.6 (−1.2, 2.3)
3 (2, 4) 0 (−2, 2)
2 (2, 5) 1 (0, 3)
Table 4 Characteristics of N = 38 participants for the Kansas City
Cardiomyopathy Questionnaire sub-study
Variable
Female (%) 21 (55.3)
Age: mean (SD) 81.9 (7.3)
BMI: mean (SD) 26.8 (6.0)
Diabetes (%) 8(21.1)
Smoking (%): never 21 (55.3)
Ex 17 (44.7)
Creatinine: mean (SD) 90.9 (33.6)
Previous MI (%) 10 (26.3)
History of pulmonary disease 12 (31.6)
Pre-operative arrhythmia 17 (44.7)
Previous cardiac surgery 13 (34.2)
Previous PCI 9 (23.7)
Left Ventricular Ejection Fraction:
≥ 50% 32 (84.2)
30–49% 5 (13.1)
< 30% 1 (2.6)
KCCQ overall summary: mean (SD) 72.6 (22.6)
KCCQ clinical summary: mean (SD) 73.6 (21.6)
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In this study, we have established the feasibility of recruit-
ing patients into a randomised trial of CR following the
TAVI procedure in a single centre. The centre operates
similar pathways and operating procedures to other UK
centres such that the conclusions are likely to generalis-
able. We will use the findings of this pilot trial to plan the
design and funding of an outcome powered UK multicen-
tre RCT to inform the provision of CR and support guide-
line development to optimise health-related quality of life
outcomes in this vulnerable population.
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